Main Uses of Rabekind Plus

Rabekind Plus is a fixed-dose combination medication primarily used for the management of gastrointestinal disorders where symptoms involve both excessive acid production and impaired gastric motility. It is commonly prescribed for individuals who do not respond adequately to single-agent acid suppressants.

Gastroesophageal Reflux Disease (GERD)

The medication is frequently used to treat GERD, a chronic condition where stomach acid flows back into the esophagus. By combining an acid inhibitor with a prokinetic agent, it helps to:

• Reduce the acidity of the gastric contents.
• Strengthen the lower esophageal sphincter.
• Accelerate the emptying of the stomach, reducing the volume of material available for reflux.

Peptic Ulcer Disease

Rabekind Plus is utilized in the management of ulcers located in the stomach or the upper part of the small intestine (duodenum). It assists in the healing process by maintaining a higher gastric pH environment, which allows the mucosal lining to repair itself without being constantly irritated by digestive acids.

Functional Dyspepsia

For patients experiencing chronic indigestion not caused by an ulcer, this combination helps alleviate symptoms such as bloating, early satiety, and upper abdominal discomfort. The prokinetic component specifically addresses the feeling of fullness and sluggish digestion.

Zollinger-Ellison Syndrome

In cases involving pathological hypersecretion of acid, such as Zollinger-Ellison Syndrome, the medication serves to control acid levels and manage the associated symptoms and risks to the intestinal lining.

Benefits of the Combination

Integrating a proton pump inhibitor with a prokinetic agent offers specific clinical advantages for certain patient profiles:

• Comprehensive Symptom Relief: It addresses both the chemical cause of discomfort (acid) and the mechanical cause (slow motility).
• Improved Gastric Emptying: By speeding up the movement of food through the digestive tract, it reduces the pressure that leads to heartburn and acid regurgitation.
• Mucosal Protection: Maintaining a stable, less acidic environment in the stomach promotes the healing of erosions and prevents further damage to the esophageal and gastric tissues.

Regulatory References

1. NIH MedlinePlus overview of Rabeprazole

The eligibility profile for Rabekind Plus (Rabeprazole and Levosulpiride) is strictly defined by regulatory bodies, identifying populations for whom use is permitted, restricted, or prohibited. The medicine is primarily intended for Adults (18 years and above) who do not have any contraindicating conditions.

---

Absolute Contraindications

Use of Rabekind Plus is prohibited for groups including:

• Known Hypersensitivity to Rabeprazole, Levosulpiride, or substituted benzimidazoles.
• Women who are pregnant or breastfeeding.
• Conditions such as GI Bleeding, Obstruction, Phaeochromocytoma, or Pituitary Prolactinoma.
• Patients with Porphyrias or those receiving Rilpivirine-containing products.

---

Restricted and Conditional Use

• Pediatric Use: The medicine is not recommended for children and adolescents (under 18 years) as safety and efficacy have not been established.
• Organ Function: Use is restricted or contraindicated in cases of Severe Hepatic Insufficiency or Severe Renal Insufficiency.
• Caution Required: Close monitoring is advised for Older Adults and patients with Cardiovascular Disease or a history of Breast Cancer.

Interactions with other medicines and products

This medicine, which combines Rabeprazole and Levosulpiride, can interact with several other medications and substances. It is essential to inform your doctor of all prescription and non-prescription drugs, supplements, and herbal products you are currently using.

Type of Interacting Product	Examples and Effect	Key Constraint or Monitoring
Antivirals (Anti-HIV)	Reduces effect of drugs like atazanavir and rilpivirine; combination with rilpivirine is generally not recommended.	Antiviral effectiveness may be decreased.
Anticoagulants (e.g., Warfarin)	May increase the blood-thinning effect.	Require close and regular monitoring of blood clotting tests.
pH-Dependent Drugs	Absorption of drugs like ketoconazole or itraconazole may be significantly reduced.	Reduced effectiveness of the interacting medicine.
Immunosuppressants	Levels of drugs like methotrexate and tacrolimus may be increased.	Requires careful dose adjustment and monitoring.
Antacids & Sucralfate	May interfere with Rabeprazole's absorption.	Take at least 2 hours apart from this medicine.
CNS Depressants & Alcohol	May increase risk of drowsiness or other side effects due to the Levosulpiride component.	Avoid or limit alcohol intake.
Digoxin, Atomoxetine	May increase the risk of irregular heart rhythm.	Use with caution and monitor cardiac status.

Note: Long-term use of the Rabeprazole component may reduce Vitamin B12 and magnesium levels, potentially requiring supplementation. Rabekind Plus can also interfere with certain laboratory tests, such as those for prolactin, Chromogranin A ( CgA), and the secretin stimulation test. Always inform laboratory staff that you are taking this medicine before any testing.

Irreversible Inhibition of the H^+/ K^+- ATPase Enzyme

The Rabeprazole component acts by permanently inhibiting the Proton Pump ( H^+/ K^+- ATPase), which is the final enzyme responsible for the secretion of acid in the stomach's parietal cells. By covalently binding to this molecular target, the drug causes a reduction in hydrogen ion concentration ( H^+), resulting in an elevation of intragastric pH.

---

️ Neurotransmitter Modulation Affecting Gastric Motility

The Levosulpiride component modulates the Enteric Nervous System (ENS) by acting as an antagonist (blocker) on peripheral Dopamine D2 receptors ( D2R). This action removes an inhibitory signal on cholinergic neurons, which in turn increases the release of Acetylcholine ( ACh) and affects smooth muscle tone and coordination. This mechanistic cascade results in the acceleration of gastric emptying and an increase in Lower Esophageal Sphincter (LES) pressure.

---

Coordination of Dual Mechanistic Pathways

The drug involves a dual-action mechanism by simultaneously modulating the chemical environment (acid suppression) and the physical environment (motility modulation) of the upper digestive tract. This coordinated approach involves parallel intervention against two distinct physiological factors: acid production and gastric clearance, resulting in a combined physiological effect.

Administration Instructions

Rabekind Plus is a fixed-dose combination medicine containing Rabeprazole 20 mg (enteric-coated) and Levosulpiride 75 mg (sustained-release). The following details define the established approach for its use.

---

Instruction Category	Standard Instruction
Route of Administration	The medicine is administered via the Oral Route.
Standard Dosing Schedule	The standard adult regimen is one capsule per day.
Timing and Frequency	The capsule must be taken once daily on an empty stomach, generally before a meal, to optimize the effect of the Rabeprazole component.
Preparation Requirements	The capsule must be swallowed whole with water; it should not be opened, chewed, or crushed.
Missed Dose Rule	If a dose is missed, take the next scheduled dose at the regular time. Do not take a double dose to make up for the missed one.
Population Rules	No dosage adjustment is typically necessary for the Rabeprazole component in patients with mild-to-moderate hepatic or renal impairment. Use in children is generally not recommended.

---

Procedural Structure

This protocol establishes a once-daily oral regimen that dictates both the method and timing of ingestion. The administration method is constrained by the capsule's specialized formulation (enteric-coated and sustained-release), requiring that its integrity must be preserved to ensure proper delivery of both active components. This structured approach governs the correct intake of the medicine.

Rabekind Plus: Recent Clinical Evidence

This section outlines the research findings for the fixed-dose combination of Rabeprazole and Levosulpiride, primarily studied for managing gastroesophageal reflux disease (GERD) and related acid-peptic disorders.

Rabeprazole and Levosulpiride Combination Studies

Clinical trials involving the combination therapy have investigated the benefits of simultaneously addressing both acid production and gastrointestinal movement. Rabeprazole, a proton pump inhibitor, is known to reduce gastric acid secretion. Levosulpiride, a prokinetic agent, is studied for its activity in increasing the pressure of the lower esophageal sphincter and improving stomach emptying. This dual activity is the focus of current combination research.

Comparative observational studies have been conducted on GERD patients to assess the combination therapy versus Rabeprazole monotherapy. These studies have reported observed improvements in symptom relief, particularly in patients presenting with specific GERD symptom profiles, such as those related to functional dyspepsia.

Safety Profile Summary

Safety assessments included data from adult populations. According to published research, common adverse events documented across trials typically include gastrointestinal issues and central nervous system effects related to the components. Research findings documented adverse events such as:

System	Reported Adverse Events (Examples)
Gastrointestinal	Nausea, vomiting, diarrhea, flatulence, abdominal pain
Nervous System	Headache, dizziness, drowsiness

It is important to note that Rabeprazole, like other proton pump inhibitors, has been associated with an increased risk of bone fractures and hypomagnesemia in patients on high doses or long-term treatment. Further, Levosulpiride has been associated with movement disorders in certain case reports, particularly with prolonged use. Research is ongoing regarding the long-term safety profile of the combination.

Common questions about Rabekind Plus (FAQ)

Q: What is Rabekind Plus?

A: Rabekind Plus is a combination product that contains a proton pump inhibitor (rabeprazole) and a prokinetic agent (levosulpiride). The proton pump inhibitor works to decrease the production of stomach acid.

Q: What is the established use for this combination?

A: The combination of rabeprazole and levosulpiride is generally studied for conditions where both acid reduction and improved gastrointestinal motility are considered relevant, such as Gastroesophageal Reflux Disease (GERD) that has been difficult to manage with acid suppressants alone.

Q: How should the contents of Rabekind Plus be considered?

A: The components of Rabekind Plus are intended to be taken as directed by a healthcare professional. Information regarding the administration, dosage, or timing of the product should be obtained from your prescribing practitioner or the official product information.

Q: What is the observed effectiveness of rabeprazole?

A: Rabeprazole has been observed to effectively reduce stomach acid production, which is utilized in managing symptoms associated with acid-related conditions. Clinical studies have suggested its role in the healing of erosive esophagitis.

Q: What is the function of levosulpiride?

A: Levosulpiride is an agent classified as a substituted benzamide. It is understood to act on specific dopamine receptors in the gastrointestinal tract, which may influence the movement and tone of the stomach and intestine.

Q: Can this product be taken long-term?

A: The appropriateness of long-term use is a clinical decision. Available data suggests that acid suppression therapy may be used for extended periods in certain conditions, but any duration of treatment should be discussed with a healthcare provider to assess the ongoing need and suitability.

Storage Requirements

Official labeling requires Rabekind Plus to be stored in a cool and dry place at a temperature not exceeding 30°C. The medicine must be protected from moisture and direct sunlight to maintain its stability. It is mandatory to keep the product in the original container or pack it came in, with the container kept tightly closed.

Handling and Child Safety

To prevent accidental exposure, the medicine must be stored out of the sight and reach of children and pets. The product is not to be used past the expiry date printed on the packaging.

Disposal Instructions

Unused or expired Rabekind Plus must be discarded properly according to instructions on the label and local regulations. The product must not be flushed in the toilet or thrown into the drain; rather, disposal should follow local pharmaceutical waste guidelines.